{"entity":{"type":"insider","cik":"0001691102","url":"/insider/0001691102","json_url":"/insider/0001691102.json","name":"Yea Christopher","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":54,"n_filings":44,"first":"2019-01-24","last":"2026-05-29","span_basis":"filed_date"},"name_variants":[{"name":"Yea Christopher","source":"filing","n_filings":44,"first_seen":"2019-01-24","last_seen":"2026-05-29"}],"transactions":[{"id":5746832,"accession":"0001691102-26-000007","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001691102-26-000007","line_url":"/filing/0001691102-26-000007#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":33800.0,"shares_display":"33,800","price_per_share":26.7818,"price_display":"26.78","price_state":"stated","total_value":905224.84,"total_display":"905,224.84","total_whole":"905,225","shares_owned_after":229918.0,"shares_owned_after_display":"229,918","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-27","filed_date":"2026-05-29","scope":"insider"},{"id":5828351,"accession":"0001691102-26-000006","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001691102-26-000006","line_url":"/filing/0001691102-26-000006#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1966.0,"shares_display":"1,966","price_per_share":26.7778,"price_display":"26.78","price_state":"stated","total_value":52645.1548,"total_display":"52,645.15","total_whole":"52,645","shares_owned_after":229918.0,"shares_owned_after_display":"229,918","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-26","filed_date":"2026-05-27","scope":"insider"},{"id":6060627,"accession":"0001691102-26-000005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001691102-26-000005","line_url":"/filing/0001691102-26-000005#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2358.0,"shares_display":"2,358","price_per_share":26.7844,"price_display":"26.78","price_state":"stated","total_value":63157.6152,"total_display":"63,157.62","total_whole":"63,158","shares_owned_after":228759.0,"shares_owned_after_display":"228,759","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-22","filed_date":"2026-05-26","scope":"insider"},{"id":5778836,"accession":"0001691102-26-000004","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001691102-26-000004","line_url":"/filing/0001691102-26-000004#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1108.0,"shares_display":"1,108","price_per_share":26.76,"price_display":"26.76","price_state":"stated","total_value":29650.08,"total_display":"29,650.08","total_whole":"29,650","shares_owned_after":227367.0,"shares_owned_after_display":"227,367","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-18","filed_date":"2026-05-19","scope":"insider"},{"id":5848869,"accession":"0001691102-26-000002","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001691102-26-000002","line_url":"/filing/0001691102-26-000002#line-3","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4347.0,"shares_display":"4,347","price_per_share":15.5668,"price_display":"15.57","price_state":"stated","total_value":67668.8796,"total_display":"67,668.88","total_whole":"67,669","shares_owned_after":226701.0,"shares_owned_after_display":"226,701","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-23","filed_date":"2026-02-24","scope":"insider"},{"id":6114610,"accession":"0001691102-26-000001","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001691102-26-000001","line_url":"/filing/0001691102-26-000001#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1109.0,"shares_display":"1,109","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":16635.0,"total_display":"16,635.00","total_whole":"16,635","shares_owned_after":224173.0,"shares_owned_after_display":"224,173","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-18","filed_date":"2026-02-19","scope":"insider"},{"id":4480185,"accession":"0001691102-25-000006","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001691102-25-000006","line_url":"/filing/0001691102-25-000006#line-3","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4331.0,"shares_display":"4,331","price_per_share":13.451,"price_display":"13.45","price_state":"stated","total_value":58256.281,"total_display":"58,256.28","total_whole":"58,256","shares_owned_after":223508.0,"shares_owned_after_display":"223,508","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-24","filed_date":"2025-11-26","scope":"insider"},{"id":4775874,"accession":"0001691102-25-000003","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001691102-25-000003","line_url":"/filing/0001691102-25-000003#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2683.0,"shares_display":"2,683","price_per_share":14.4794,"price_display":"14.48","price_state":"stated","total_value":38848.2302,"total_display":"38,848.23","total_whole":"38,848","shares_owned_after":133574.0,"shares_owned_after_display":"133,574","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-18","filed_date":"2025-11-19","scope":"insider"},{"id":4953288,"accession":"0001415889-25-023070","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-023070","line_url":"/filing/0001415889-25-023070#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1954.0,"shares_display":"1,954","price_per_share":13.42,"price_display":"13.42","price_state":"stated","total_value":26222.68,"total_display":"26,222.68","total_whole":"26,223","shares_owned_after":132052.0,"shares_owned_after_display":"132,052","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-25","filed_date":"2025-08-26","scope":"insider"},{"id":4501935,"accession":"0001415889-25-022968","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-022968","line_url":"/filing/0001415889-25-022968#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2362.0,"shares_display":"2,362","price_per_share":13.2228,"price_display":"13.22","price_state":"stated","total_value":31232.2536,"total_display":"31,232.25","total_whole":"31,232","shares_owned_after":130881.0,"shares_owned_after_display":"130,881","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-22","filed_date":"2025-08-25","scope":"insider"},{"id":4054959,"accession":"0001415889-25-022306","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-022306","line_url":"/filing/0001415889-25-022306#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2649.0,"shares_display":"2,649","price_per_share":13.187,"price_display":"13.19","price_state":"stated","total_value":34932.363,"total_display":"34,932.36","total_whole":"34,932","shares_owned_after":129493.0,"shares_owned_after_display":"129,493","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-19","scope":"insider"},{"id":4684089,"accession":"0001415889-25-019656","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-019656","line_url":"/filing/0001415889-25-019656#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30250.0,"shares_display":"30,250","price_per_share":15.6925,"price_display":"15.69","price_state":"stated","total_value":474698.125,"total_display":"474,698.12","total_whole":"474,698","shares_owned_after":127939.0,"shares_owned_after_display":"127,939","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-09","filed_date":"2025-07-10","scope":"insider"},{"id":4036456,"accession":"0001415889-25-014600","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-014600","line_url":"/filing/0001415889-25-014600#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1926.0,"shares_display":"1,926","price_per_share":11.3093,"price_display":"11.31","price_state":"stated","total_value":21781.7118,"total_display":"21,781.71","total_whole":"21,782","shares_owned_after":98189.0,"shares_owned_after_display":"98,189","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-23","filed_date":"2025-05-27","scope":"insider"},{"id":5080802,"accession":"0001415889-25-014475","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-014475","line_url":"/filing/0001415889-25-014475#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2317.0,"shares_display":"2,317","price_per_share":11.8755,"price_display":"11.88","price_state":"stated","total_value":27515.5335,"total_display":"27,515.53","total_whole":"27,516","shares_owned_after":96990.0,"shares_owned_after_display":"96,990","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-22","filed_date":"2025-05-23","scope":"insider"},{"id":4146506,"accession":"0001415889-25-013870","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-013870","line_url":"/filing/0001415889-25-013870#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2600.0,"shares_display":"2,600","price_per_share":11.8428,"price_display":"11.84","price_state":"stated","total_value":30791.28,"total_display":"30,791.28","total_whole":"30,791","shares_owned_after":95557.0,"shares_owned_after_display":"95,557","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-19","filed_date":"2025-05-20","scope":"insider"},{"id":4210662,"accession":"0001415889-25-005613","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-005613","line_url":"/filing/0001415889-25-005613#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1918.0,"shares_display":"1,918","price_per_share":10.02,"price_display":"10.02","price_state":"stated","total_value":19218.36,"total_display":"19,218.36","total_whole":"19,218","shares_owned_after":93952.0,"shares_owned_after_display":"93,952","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-24","filed_date":"2025-02-25","scope":"insider"},{"id":5153281,"accession":"0001415889-25-004773","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-004773","line_url":"/filing/0001415889-25-004773#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2601.0,"shares_display":"2,601","price_per_share":9.8242,"price_display":"9.82","price_state":"stated","total_value":25552.7442,"total_display":"25,552.74","total_whole":"25,553","shares_owned_after":92745.0,"shares_owned_after_display":"92,745","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-18","filed_date":"2025-02-19","scope":"insider"},{"id":2954887,"accession":"0001415889-24-027908","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-027908","line_url":"/filing/0001415889-24-027908#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1963.0,"shares_display":"1,963","price_per_share":9.8718,"price_display":"9.87","price_state":"stated","total_value":19378.3434,"total_display":"19,378.34","total_whole":"19,378","shares_owned_after":91142.0,"shares_owned_after_display":"91,142","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-26","filed_date":"2024-11-27","scope":"insider"},{"id":2757062,"accession":"0001415889-24-027273","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-027273","line_url":"/filing/0001415889-24-027273#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7192.0,"shares_display":"7,192","price_per_share":9.2565,"price_display":"9.26","price_state":"stated","total_value":66572.748,"total_display":"66,572.75","total_whole":"66,573","shares_owned_after":89980.0,"shares_owned_after_display":"89,980","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-18","filed_date":"2024-11-19","scope":"insider"},{"id":2756383,"accession":"0001415889-24-022257","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-022257","line_url":"/filing/0001415889-24-022257#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1916.0,"shares_display":"1,916","price_per_share":12.4,"price_display":"12.40","price_state":"stated","total_value":23758.4,"total_display":"23,758.40","total_whole":"23,758","shares_owned_after":85676.0,"shares_owned_after_display":"85,676","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-23","filed_date":"2024-08-26","scope":"insider"},{"id":2044049,"accession":"0001415889-24-021968","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-021968","line_url":"/filing/0001415889-24-021968#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7102.0,"shares_display":"7,102","price_per_share":12.0133,"price_display":"12.01","price_state":"stated","total_value":85318.4566,"total_display":"85,318.46","total_whole":"85,318","shares_owned_after":84467.0,"shares_owned_after_display":"84,467","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-19","filed_date":"2024-08-21","scope":"insider"},{"id":2530171,"accession":"0001415889-24-014000","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-014000","line_url":"/filing/0001415889-24-014000#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11610.0,"shares_display":"11,610","price_per_share":11.7645,"price_display":"11.76","price_state":"stated","total_value":136585.845,"total_display":"136,585.84","total_whole":"136,586","shares_owned_after":80074.0,"shares_owned_after_display":"80,074","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-20","filed_date":"2024-05-21","scope":"insider"},{"id":2995512,"accession":"0001415889-24-004716","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-004716","line_url":"/filing/0001415889-24-004716#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12053.0,"shares_display":"12,053","price_per_share":14.1147,"price_display":"14.11","price_state":"stated","total_value":170124.4791,"total_display":"170,124.48","total_whole":"170,124","shares_owned_after":72895.0,"shares_owned_after_display":"72,895","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-20","filed_date":"2024-02-21","scope":"insider"},{"id":2440307,"accession":"0001415889-24-004117","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-004117","line_url":"/filing/0001415889-24-004117#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF DEVELOPMENT OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF DEVELOPMENT OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":39886.0,"shares_display":"39,886","price_per_share":15.0093,"price_display":"15.01","price_state":"stated","total_value":598660.9398,"total_display":"598,660.94","total_whole":"598,661","shares_owned_after":66160.0,"shares_owned_after_display":"66,160","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-14","filed_date":"2024-02-16","scope":"insider"},{"id":7973953,"accession":"0001209191-23-056272","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-056272","line_url":"/filing/0001209191-23-056272#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7113.0,"shares_display":"7,113","price_per_share":8.2293,"price_display":"8.23","price_state":"stated","total_value":58535.0109,"total_display":"58,535.01","total_whole":"58,535","shares_owned_after":46046.0,"shares_owned_after_display":"46,046","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-20","filed_date":"2023-11-21","scope":"insider"},{"id":8222100,"accession":"0001209191-23-046822","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-046822","line_url":"/filing/0001209191-23-046822#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7142.0,"shares_display":"7,142","price_per_share":10.7287,"price_display":"10.73","price_state":"stated","total_value":76624.3754,"total_display":"76,624.38","total_whole":"76,624","shares_owned_after":41662.0,"shares_owned_after_display":"41,662","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-18","filed_date":"2023-08-21","scope":"insider"},{"id":7950827,"accession":"0001209191-23-031295","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-031295","line_url":"/filing/0001209191-23-031295#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2604.0,"shares_display":"2,604","price_per_share":10.1444,"price_display":"10.14","price_state":"stated","total_value":26416.0176,"total_display":"26,416.02","total_whole":"26,416","shares_owned_after":37310.0,"shares_owned_after_display":"37,310","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-18","filed_date":"2023-05-19","scope":"insider"},{"id":8627747,"accession":"0001209191-23-012317","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-012317","line_url":"/filing/0001209191-23-012317#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2727.0,"shares_display":"2,727","price_per_share":7.66,"price_display":"7.66","price_state":"stated","total_value":20888.82,"total_display":"20,888.82","total_whole":"20,889","shares_owned_after":35709.0,"shares_owned_after_display":"35,709","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-17","filed_date":"2023-02-23","scope":"insider"},{"id":6186719,"accession":"0001209191-22-058136","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-058136","line_url":"/filing/0001209191-22-058136#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1139.0,"shares_display":"1,139","price_per_share":5.44,"price_display":"5.44","price_state":"stated","total_value":6196.16,"total_display":"6,196.16","total_whole":"6,196","shares_owned_after":34232.0,"shares_owned_after_display":"34,232","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-18","filed_date":"2022-11-21","scope":"insider"},{"id":6126532,"accession":"0001209191-22-046880","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-046880","line_url":"/filing/0001209191-22-046880#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1145.0,"shares_display":"1,145","price_per_share":14.9607,"price_display":"14.96","price_state":"stated","total_value":17130.0015,"total_display":"17,130.00","total_whole":"17,130","shares_owned_after":33597.0,"shares_owned_after_display":"33,597","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-17","filed_date":"2022-08-19","scope":"insider"},{"id":4741686,"accession":"0001209191-21-062730","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-062730","line_url":"/filing/0001209191-21-062730#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":18.0656,"price_display":"18.07","price_state":"stated","total_value":90328.0,"total_display":"90,328.00","total_whole":"90,328","shares_owned_after":32969.0,"shares_owned_after_display":"32,969","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-01","filed_date":"2021-11-03","scope":"insider"},{"id":4572839,"accession":"0001209191-21-049800","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-049800","line_url":"/filing/0001209191-21-049800#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":20.5157,"price_display":"20.52","price_state":"stated","total_value":102578.5,"total_display":"102,578.50","total_whole":"102,579","shares_owned_after":37969.0,"shares_owned_after_display":"37,969","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-02","filed_date":"2021-08-04","scope":"insider"},{"id":4272996,"accession":"0001209191-21-030755","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-030755","line_url":"/filing/0001209191-21-030755#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":24.8393,"price_display":"24.84","price_state":"stated","total_value":124196.5,"total_display":"124,196.50","total_whole":"124,197","shares_owned_after":42969.0,"shares_owned_after_display":"42,969","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-03","filed_date":"2021-05-06","scope":"insider"},{"id":5322094,"accession":"0001209191-21-014518","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-014518","line_url":"/filing/0001209191-21-014518","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":33.59182145333333,"price_display":"33.59","price_state":"stated","total_value":503877.3218,"total_display":"503,877.32","total_whole":"503,877","shares_owned_after":51780.0,"shares_owned_after_display":"51,780","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-23","filed_date":"2021-02-25","scope":"insider","n_lines":4},{"id":2690216,"accession":"0001209191-20-056468","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-056468","line_url":"/filing/0001209191-20-056468#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":17.4788,"price_display":"17.48","price_state":"stated","total_value":87394.0,"total_display":"87,394.00","total_whole":"87,394","shares_owned_after":62969.0,"shares_owned_after_display":"62,969","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-29","filed_date":"2020-11-02","scope":"insider"},{"id":2558589,"accession":"0001209191-20-055590","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-055590","line_url":"/filing/0001209191-20-055590","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6044.0,"shares_display":"6,044","price_per_share":18.246461085373923,"price_display":"18.25","price_state":"stated","total_value":110281.6108,"total_display":"110,281.61","total_whole":"110,282","shares_owned_after":70513.0,"shares_owned_after_display":"70,513","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-21","filed_date":"2020-10-22","scope":"insider","n_lines":2},{"id":2558580,"accession":"0001209191-20-055590","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-20-055590","line_url":"/filing/0001209191-20-055590","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7942.0,"shares_display":"7,942","price_per_share":17.48750599345253,"price_display":"17.49","price_state":"stated","total_value":138885.7726,"total_display":"138,885.77","total_whole":"138,886","shares_owned_after":76315.0,"shares_owned_after_display":"76,315","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-20","filed_date":"2020-10-22","scope":"insider","n_lines":2},{"id":3284836,"accession":"0001209191-20-055365","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-055365","line_url":"/filing/0001209191-20-055365#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":914.0,"shares_display":"914","price_per_share":17.0014,"price_display":"17.00","price_state":"stated","total_value":15539.2796,"total_display":"15,539.28","total_whole":"15,539","shares_owned_after":81955.0,"shares_owned_after_display":"81,955","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-16","filed_date":"2020-10-20","scope":"insider"},{"id":2097081,"accession":"0001567619-20-002454","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-20-002454","line_url":"/filing/0001567619-20-002454#line-1","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":17.1,"price_display":"17.10","price_state":"stated","total_value":1710.0,"total_display":"1,710.00","total_whole":"1,710","shares_owned_after":82869.0,"shares_owned_after_display":"82,869","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-05","filed_date":"2020-02-07","scope":"insider"},{"id":8290080,"accession":"0001567619-19-023612","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-19-023612","line_url":"/filing/0001567619-19-023612#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2646.0,"shares_display":"2,646","price_per_share":17.0163,"price_display":"17.02","price_state":"stated","total_value":45025.1298,"total_display":"45,025.13","total_whole":"45,025","shares_owned_after":82969.0,"shares_owned_after_display":"82,969","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-20","filed_date":"2019-12-26","scope":"insider"},{"id":8610852,"accession":"0001567619-19-023163","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001567619-19-023163","line_url":"/filing/0001567619-19-023163#line-6","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3010.0,"shares_display":"3,010","price_per_share":17.0493,"price_display":"17.05","price_state":"stated","total_value":51318.393,"total_display":"51,318.39","total_whole":"51,318","shares_owned_after":82969.0,"shares_owned_after_display":"82,969","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-16","filed_date":"2019-12-16","scope":"insider"},{"id":8610847,"accession":"0001567619-19-023163","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001567619-19-023163","line_url":"/filing/0001567619-19-023163#line-4","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":17.0453,"price_display":"17.05","price_state":"stated","total_value":25567.95,"total_display":"25,567.95","total_whole":"25,568","shares_owned_after":82969.0,"shares_owned_after_display":"82,969","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-13","filed_date":"2019-12-16","scope":"insider"},{"id":8610843,"accession":"0001567619-19-023163","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-19-023163","line_url":"/filing/0001567619-19-023163#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":199.0,"shares_display":"199","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":3383.0,"total_display":"3,383.00","total_whole":"3,383","shares_owned_after":82969.0,"shares_owned_after_display":"82,969","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-12-12","filed_date":"2019-12-16","scope":"insider"},{"id":7957937,"accession":"0001567619-19-015142","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-19-015142","line_url":"/filing/0001567619-19-015142#line-2","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7355.0,"shares_display":"7,355","price_per_share":18.3453,"price_display":"18.35","price_state":"stated","total_value":134929.6815,"total_display":"134,929.68","total_whole":"134,930","shares_owned_after":82969.0,"shares_owned_after_display":"82,969","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-07-22","filed_date":"2019-07-24","scope":"insider"},{"id":8018268,"accession":"0001567619-19-009061","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-19-009061","line_url":"/filing/0001567619-19-009061#line-3","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"KalVista Pharmaceuticals, Inc.","issuer_ticker":"KALV","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":"0001691102","owner_name":"Yea Christopher","owner_display_name":"Yea Christopher","owner_url":"/insider/0001691102","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6355.0,"shares_display":"6,355","price_per_share":25.9235,"price_display":"25.92","price_state":"stated","total_value":164743.8425,"total_display":"164,743.84","total_whole":"164,744","shares_owned_after":83969.0,"shares_owned_after_display":"83,969","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-04-22","filed_date":"2019-04-23","scope":"insider"}],"collapsed":true,"next_cursor":"2019-04-22|8018268","ledger_fault":false,"count":{"value":54,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":54,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":54},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001348911","name":"KalVista Pharmaceuticals, Inc.","url":"/issuer/0001348911","role":"Officer (CHIEF DEVELOPMENT OFFICER)","n_filings":44,"first_seen":"2019-01-24","last_seen":"2026-05-29"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001691102","retrieved_at":"2026-08-22T05:31:32+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}